PGPIPN, a hexapeptide derived from the 63-68 amino acid residue of bovine β-casein 181, reduced the resistance of ovarian cancer cells to cisplatin by affecting the HSF1/HSP70 signaling pathway. Here, HSF1 is linked to ovarian carcinoma.